Literature DB >> 27355366

Melanoma cell adhesion molecule as an emerging biomarker with prognostic significance in systolic heart failure.

Joanna Banach1, Magdalena Grochowska1, Lidia Gackowska2, Katarzyna Buszko3, Robert Bujak1, Wojciech Gilewski1, Izabela Kubiszewska2, Łukasz Wołowiec1, Jacek Michałkiewicz2, Władysław Sinkiewicz1.   

Abstract

BACKGROUND: Melanoma cell adhesion molecule (MCAM) is a marker of endothelial damage. MCAM diagnostic and prognostic value was assessed in chronic heart failure (CHF). MATERIALS &
METHODS: 130 CHF patients and 32 controls were included in the study. Telephone follow-up lasted one year. End points were: death from all causes, and hospitalization with CHF exacerbation.
RESULTS: MCAM was higher in patients than in controls (p = 0.01). Receiver operator curve analysis revealed that MCAM may serve as a predictor of death (area under the curve: 0.8404; p < 0.002). Patients with MCAM above 500 ng/ml had worse prognosis (p = 0.03). NT-proBNP and age were independent predictors of death in multivariate analysis.
CONCLUSION: The increased MCAM indicates endothelial damage in CHF and may serve as a marker of worse prognosis in these patients.

Entities:  

Keywords:  chronic heart failure; melanoma cell adhesion molecule; prognosis

Mesh:

Substances:

Year:  2016        PMID: 27355366     DOI: 10.2217/bmm-2016-0053

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

1.  Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF).

Authors:  J Banach; Ł Wołowiec; D Rogowicz; L Gackowska; I Kubiszewska; W Gilewski; J Michałkiewicz; W Sinkiewicz
Journal:  Dis Markers       Date:  2018-08-28       Impact factor: 3.434

2.  Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up.

Authors:  Łukasz Wołowiec; Daniel Rogowicz; Joanna Banach; Wojciech Gilewski; Władysław Sinkiewicz; Grzegorz Grześk
Journal:  Dis Markers       Date:  2020-10-01       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.